Replies to post #80321 on Ayala Pharmaceuticals Inc (ADXS)

[jckrdu]

Agree. A PR on 1 patient is unlikely, but IMO possible if they did see a CR. The company is fighting for its future, and with an open-label study they can disclose what they want, when they want.

I'm not expecting data news until the 1st half of 2019 as they guided, but wouldn't be surprised to see news sooner if this relatively new neoantigen approach yielded a CR in the very first patient treated.

[ignatiusrielly35]

Word of that would spread through the grapevine regardless.